Greg is currently Associate Director of Molecular Biology at Precigen Therapeutics, where he leads research programs developing next-generation gene and cell therapies. Previously, he was a Scientist at Denali Therapeutics, where he helped advance a small molecule therapeutic program from the lab bench into clinical trials. Over the past 25 years, he has built a career that bridges academia and industry, with expertise spanning neuroscience, immunotherapy, biologics, and drug development. Greg received his Ph.D. in Neuroscience from Johns Hopkins University School of Medicine.
During his postdoctoral work at UCSF, Greg discovered the underlying mutation in a novel Krabbe disease mouse model. He and his wife later established a small research group at OHSU in Portland, Oregon, where they continued to investigate the molecular mechanisms and disease processes of Krabbe disease using this model. As part of this work, Greg’s group received a research grant from the Legacy of Angels Foundation (now RFRF), funding that was instrumental in supporting their lab. He remains grateful for that support and is honored to return to the Foundation as a Board member. Greg brings a combined scientific and industry perspective to support strategic planning and to help accelerate therapies for rare diseases.
Outside of work, Greg enjoys running, tennis, pickleball, science fiction books and movies, and spending time hiking and exploring the outdoors with his family.